The technology was developed at the Massachusetts Institute of Technology (MIT) by Robert Langer, PhD, and Ana Jaklenec, PhD.

Single injection vaccine delivery releases two to 10 doses over different time points and could address the problem of lack of patient compliance with multiple vaccine dose appointments, the company said. It could improve the uptake of vaccines for HPV, hepatitis B, rabies, polio, malaria, and shingles, and could also help researchers develop new vaccines for diseases like HIV and COVID-19.

The company will use the funds to demonstrate the efficacy in animals using rabies as a model vaccine. The company's option agreement with MIT provides for evaluation of the technology and the option to negotiate for an exclusive global license to a wide variety of vaccines for infectious diseases, as well as a nonexclusive global license to vaccines for SARS-CoV-2.

Can vaccine resistance be predicted with test samples?
The likelihood of SARS-CoV-2 developing resistance to COVID-19 vaccines currently under development can be determined using repurposed blood and nasal...

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

European org issues guidance for viral vector COVID-19 vaccines
The European Directorate for the Quality of Medicines & Healthcare of the Council of Europe issued a new document on the use of recombinant viral...

Most antibody responses to SARS-CoV-2 are strong and long-lasting
How long does the immune response last in patients with the SARS-CoV-2 virus? This has been a key question in shaping the public health response to the...

New model could improve vaccine, immunotherapy design
A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies...